Ocular Therapeutix Inc. (NASDAQ:OCUL) is likely one of the low priced shares to purchase with excessive upside potential. On December 12, Financial institution of America raised the agency’s value goal on Ocular Therapeutix to $21 from $18 and maintained a Purchase score on the shares. After internet hosting CEO Pravin Dugel to evaluate upcoming company milestones, the agency highlighted the event technique for AXPAXLI, supported by pivotal trials in each moist AMD and diabetic retinopathy. BofA stays optimistic in regards to the drug’s distinctive aggressive benefits and the potential for a sooner regulatory path.
On December 8, Ocular Therapeutix Inc. (NASDAQ:OCUL) introduced a serious acceleration of its regulatory technique for AXPAXLI (OTX-TKI), which is an investigational therapy for moist age-related macular degeneration (moist AMD). The corporate now plans to submit an NDA shortly after receiving one-year knowledge from its SOL-1 Section 3 trial, supplied the outcomes are optimistic. These topline outcomes stay on observe for launch in Q1 2026.
The accelerated timeline is supported by latest FDA steerage suggesting {that a} single, well-powered registrational trial could suffice for approval, reasonably than the standard requirement of two research. Ocular Therapeutix Inc. (NASDAQ:OCUL) believes SOL-1 meets these excessive requirements as a result of it’s a superiority trial and is carried out below a Particular Protocol Evaluation settlement. The SOL-1 research itself accomplished randomization in December 2024 with 344 treatment-naïve topics. It compares AXPAXLI in opposition to a 2 mg dose of aflibercept, with a main endpoint measuring the proportion of sufferers who keep visible acuity at week 36.
Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical firm that develops and commercializes therapies for retinal illnesses and different eye circumstances utilizing its bioresorbable hydrogel-based formulation know-how within the US.
Whereas we acknowledge the potential of OCUL as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. In the event you’re searching for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: 30 Shares That Ought to Double in 3 Years and 11 Hidden AI Shares to Purchase Proper Now.
Disclosure: None. This text is initially printed at Insider Monkey.